{"id":"natalizumab-ntz","safety":{"commonSideEffects":[{"rate":null,"effect":"Progressive multifocal leukoencephalopathy (PML)"},{"rate":"20–30","effect":"Headache"},{"rate":"15–25","effect":"Fatigue"},{"rate":"10–20","effect":"Arthralgia"},{"rate":"10–15","effect":"Infusion reactions"},{"rate":"5–10","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to α4β1 integrin, natalizumab inhibits the adhesion and transmigration of lymphocytes across the blood-brain barrier and into inflamed tissues. This reduces the infiltration of autoreactive immune cells into the brain and spinal cord, thereby decreasing inflammation and demyelination in multiple sclerosis. The mechanism also applies to gut-homing lymphocytes, which is relevant to its use in Crohn's disease.","oneSentence":"Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:49.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Crohn's disease (moderate to severe)"}]},"trialDetails":[{"nctId":"NCT05701423","phase":"","title":"A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2023-02-08","conditions":"Multiple Sclerosis","enrollment":34},{"nctId":"NCT05209815","phase":"","title":"Safety of Exposure to Natalizumab During Pregnancy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2022-06-20","conditions":"Multiple Sclerosis","enrollment":68},{"nctId":"NCT02769689","phase":"PHASE4","title":"Methylprednisolone During the Switch Between Natalizumab and Fingolimod","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-12","conditions":"Multiple Sclerosis","enrollment":56},{"nctId":"NCT02588053","phase":"","title":"Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"natalizumab (NTZ)","genericName":"natalizumab (NTZ)","companyName":"University Hospital, Clermont-Ferrand","companyId":"university-hospital-clermont-ferrand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system. Used for Relapsing-remitting multiple sclerosis, Crohn's disease (moderate to severe).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}